Loading…

Loading grant details…

Active HORIZON European Commission

Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles


Funder European Commission
Recipient Organization Diamante Societa Benefit S.R.L
Country Italy
Start Date Jan 01, 2025
End Date Dec 31, 2026
Duration 729 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101189019
Grant Description

At Diamante Societ Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs mode of action is based on Antigen Specific Immunotehrapy.

This means that our VNPs are able to re-educate the immune system to immune tolerate the specific bodys own cell (autoantigen) causing the disease.

Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms.

Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects.

Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune systems ability to defend itself; hence reducing potential harmful side effects.We are now seeking funding to cover the next clinical development steps.

All Grantees

Diamante Societa Benefit S.R.L

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant